3D printing Report

3D Bioprinting 2017-2027: Technologies, Markets, Forecasts

Opportunities in cosmetics and consumer product testing, drug development and regenerative medicine

The market for 3D bioprinting will reach $1.8 billion by 2027
 

Order now

Table of Contents
1.EXECUTIVE SUMMARY
1.1.Overview
1.2.3D Bioprinting Players
1.3.High Profile Partnerships
1.4.Successful Animal Tests
1.5.3D Bioprinting Market Forecast 2017 - 2027
1.6.3D Bioprinter Market Forecast 2017 - 2027
1.7.3D Bioprinted Tissue Market Forecast 2017 - 2027
1.8.Key Drivers
1.9.Key Challenges
2.INTRODUCTION
2.1.Report Scope / 3D Bioprinting Definition
2.2.3D Bioprinting Process
2.2.1.3D Bioprinting Process: Discussion
2.3.3D Cell Culture Advantages
2.4.3D Bioprinting Advantages
2.5.Key Driver: Regenerative Medicine
2.5.1.Key Driver: Unmet Need in Organs for Transplant
2.6.Key Driver: Product Testing in Medicine
2.6.1.Key Driver: Avoiding Costly Drug Trial Failures
2.7.Key Driver: Product Testing in Consumer Products
2.8.Major Bioprinting Firsts
2.9.3D Bioprinting in 2017
2.10.Key Trends: 3D Bioprinters
2.11.Key Trends: Bioprinted Tissues
2.12.Key Competing Technologies
2.13.Current Technical Challenges
2.14.Current Biological Challenges
2.15.Regulatory Hurdles
2.16.3D Bioprinting SWOT Analysis
3.3D BIOPRINTER TECHNOLOGIES
3.1.From 3D Printing to 3D Bioprinting
3.2.3D Bioprinting Technologies
3.2.1.Comparison of Key Specifications
3.3.3D Bioprinting Technology Comparison
3.4.Inkjet: Introduction
3.4.1.Inkjet: Key Specifications
3.4.2.Inkjet: Thermal
3.4.3.Inkjet: Piezoelectric
3.4.4.Inkjet: Advantages
3.4.5.Inkjet: Challenges
3.4.6.Inkjet: SWOT Analysis
3.5.Extrusion: Introduction
3.5.1.Extrusion: Key Specifications
3.5.2.Extrusion: Pneumatic
3.5.3.Extrusion: Mechanical
3.5.4.Extrusion: Advantages
3.5.5.Extrusion: Challenges
3.5.6.Extrusion: SWOT Analysis
3.6.Laser: Introduction
3.6.1.LIFT: Key Specifications
3.6.2.LIFT: Laser-Induced Forward Transfer
3.6.3.LIFT: Advantages
3.6.4.LIFT: Challenges
3.6.5.LIFT: SWOT Analysis
3.7.Microvalve: Introduction
3.7.1.Microvalve: Key Specifications
3.7.2.Microvalve: Solenoid
3.7.3.Microvalve: Advantages
3.7.4.Microvalve: Challenges
3.7.5.Microvalve: SWOT Analysis
3.8.Emerging Technology
3.8.1.Emerging Technology: Electrospinning
3.8.2.Emerging Technology: Microscale Continuous Optical Bioprinting (µCOB)
3.8.3.Emerging Technology: Paramagnetic and Acoustic
3.9.Industry-wide Technical Challenges
3.10.The Ideal 3D Bioprinter
3.11.Future Technological Directions
4.RELATED TECHNOLOGIES
4.1.Related Technologies
4.2.3D Bioprinting Software
4.3.Bioink Preparation
4.4.Cell Selection
4.4.1.Cell Selection: Regenerative Medicine
4.5.Growth Factors and Other Additives
4.6.Scaffold Materials
4.7.The Ideal Scaffold Material
4.8.Cell Spheroid Printing
4.9.Maturation
5.APPLICATIONS
5.1.Introduction
5.2.Testing of Cosmetics and Other Consumer Goods
5.3.Drug Screening
5.3.1.Drug Screening: Drug Development Process
5.3.2.Drug Screening: Benefits of 3D Bioprinting
5.4.Personalised Medicine
5.5.Regenerative Medicine
5.5.1.Regenerative Medicine: Tissue Roadmap
5.5.2.Regenerative Medicine: Bone and cartilage
5.5.3.Regenerative Medicine: Skin
5.5.4.Regenerative Medicine: Dental
5.5.5.Regenerative Medicine: Vasculature
5.5.6.Regenerative Medicine: Complex Organs
5.6.Cell-Based Biosensors
5.7.Food and Other Animal Products
5.8.Education
5.9.Academic Research
5.10.Bionics
6.MARKETS AND FORECASTS
6.1.Introduction
6.2.Growing 3D Bioprinting Market
6.3.Market Barriers
6.4.Key Losers
6.5.Forecasts
6.6.Overall 3D Bioprinting Market Forecast 2017 - 2027
6.6.1.Overall 3D Bioprinting Market Forecast: Short and Long Term
6.7.3D Bioprinting Value Chain
6.7.1.3D Bioprinting Value Chain: Discussion
6.8.3D Bioprinter Manufacturers
6.8.1.3D Bioprinters by Cost and Technology
6.9.3D Bioprinter Market Forecast 2017 - 2027
6.9.1.3D Bioprinter Market Forecast: Short Term
6.9.2.3D Bioprinter Market Forecast: Long Term
6.10.3D Bioprinting Service Bureaus
6.11.3D Bioprinted Tissue Forecast 2017 - 2027
6.11.1.3D Bioprinted Tissue Forecast: Consumer Products
6.11.2.3D Bioprinted Tissue Forecast: Pharmaceuticals
6.11.3.3D Bioprinted Tissue Forecast: Others
7.REGENERATIVE MEDICINE
7.1.Introduction
7.2.Regulatory Hurdles
7.3.Regenerative Medicine Advanced Therapy Designation
7.4.Ethics
7.5.Scams and Schemes
7.6.From Lab to Clinic
7.7.3D Bioprinting Roadmap to 2050
8.APPENDIX
8.1.List of 3D Bioprinting Companies
8.2.List of Company Profiles
8.2.1.3D Bioprinting Solutions/Vivax Bio
8.2.2.3Dynamic Systems Ltd
8.2.3.Aether Inc.
8.2.4.Aspect Biosystems
8.2.5.Biobots
8.2.6.BioDan Group
8.2.7.Cellenion SASU
8.2.8.Cellink
8.2.9.Digilab Inc.
8.2.10.GeSIM
8.2.11.Microdrop Technologies GmbH
8.2.12.MicroFab
8.2.13.Organovo Holdings, Inc.
8.2.14.PeptiGelDesign Ltd
8.2.15.Poietis
8.2.16.Regemat 3D
8.2.17.SE3D
8.2.18.Sichuan Revotek Co. Ltd.

Report Statistics

-Slides184
-Companies18
-Forecasts to2027
-Last updateSep 2017
 

Downloads

pdf Document Webinar slides
pdf Document Sample pages